Overexpression of the MDM2 oncogene in leukemia and lymphoma - PubMed (original) (raw)

Review

. 1996 May;21(5-6):391-7, color plates XVI following 5.

doi: 10.3109/10428199609093436.

Affiliations

Review

Overexpression of the MDM2 oncogene in leukemia and lymphoma

T Watanabe et al. Leuk Lymphoma. 1996 May.

Abstract

A cellular phosphoprotein that binds to and inactivates p53 has recently been identified as a product of the oncogene MDM2. Amplification of the MDM2 gene was found in more than a third of sarcomas and in a subset of malignant gliomas. Despite the absence of amplification, the MDM2 gene was overexpressed in some types of leukemias and lymphomas. Overexpression was significantly more frequent in the low-grade type of B-cell non-Hodgkin's lymphoma (B-NHL) than in the intermediate/high grade types of lymphoma and the overexpression was also significantly more frequent in the advanced rather than the earlier stages of B-cell chronic lymphocytic leukemia (B-CLL) and B-NHL. This suggests that MDM2 could play a role, via the p53 pathway, in tumorigenicity and/or in disease progression in some hematological malignancies. However, in the light of our findings that, in a few cases, both the overexpression of MDM2 and mutant-type p53 was seen, it is possible that MDM2 overexpression may also promote neoplastic growth by mechanisms other than inactivation of the p53 protein.

PubMed Disclaimer

Publication types

MeSH terms

Substances

LinkOut - more resources